Volastra Aims To Terminate Cancer Relying On Chromosomal Instability

Volastra Therapeutics has a goal to exploit chromosomal instability (CIN) – the process by which cancer cells divide and are able to evade the body’s normal responses – to develop a new category of cancer therapeutics. With venture capital support from big investors including Polaris Partners and ARCH Ventures, the New York City-based start-up has advanced two potential first-in-class drugs into clinical development within five years of its founding.

“What we’ve spent the last five years doing is really being a biology-focused company where we can understand chromosomal instability in a way that no one has tackled up until...